HomeAuthorsPosts by Sam Atkinson

Sam Atkinson

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge in profit for the third quarter ended May 31, 2026. This performance marks a decisive shift from a period of recovery toward a new phase of resilient growth in the...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the country grapples with a growing burden of non-communicable diseases (NCDs), particularly diabetes and chronic kidney disease. Recent estimates show that one-in-six Malaysians has diabetes, while one-in-seven is at risk of chronic...
spot_img

Keep exploring

SGX-LISTED COMPANIES

Inside Aztech Global’s 54% Revenue Jump In Q1 2026

5 Investor Takeaways from Aztech Global’s Q1 2026 In a global manufacturing landscape currently defined...
SGX-LISTED COMPANIES

How Fortress Minerals FY2026 Is Defying The Global Steel Slump

A Tale of Two Realities The global steel market is currently navigating a period of...
SGX-LISTED COMPANIES

Unpacking World Precision Machinery’s Turbulent Q1 2026

The Machinery Giant Pivoting to Hotels The name "World Precision Machinery" suggests a corporate identity...
SGX-LISTED COMPANIES

Mapletree Pan Asia Commercial Trust Deliberately Shrinks In Q4 FY2026

Why “Shrinking” is the New Path to Resilience In the current global economic landscape, investors...
SGX-LISTED COMPANIES

Singapore’s Malls Are Defying The Global Retail Slump – Frasers Centrepoint Trust H1 FY2026

5 Takeaways from FCT’s H1 FY2026 Results The global narrative surrounding retail real estate has...
SGX-LISTED COMPANIES

Nomura Is Reinventing Its Global Strategy In FY2026

Nomura is often categorized as a stalwart of traditional Japanese finance, a legacy institution...
SGX-LISTED COMPANIES

iFAST Breaks Records In Q1 2026 – But Can It Really Reach $100B By 2030?

Global markets are currently a theater of nerves. Between geopolitical flashpoints in Iran and...
SGX-LISTED COMPANIES

What ZICO Holdings Q1 2026 Restructuring Really Means

The professional services landscape in Southeast Asia is currently a complex tapestry of shifting...
SGX-LISTED COMPANIES

Why ISEC Healthcare’s Q1 2026 Profit Dip Isn’t What It Seems

In the world of financial reporting, a double-digit drop in net profit is usually...
SGX-LISTED COMPANIES

Why Abundante’s 11% Revenue Jump Led To A 98% Profit Crash In FY2026

Lessons from Abundante’s FY2026 Results In the world of corporate finance, the relationship between top-line...
SGX-LISTED COMPANIES

ISOTeam Secures S$30.1M In New Contracts As Order Book Grows To S$186.5M

Drones, Dividends, and the Future of Singapore's HDBs: The Surprising Tech Pivot of ISOTeam Scaffolding...
SGX-LISTED COMPANIES

TSH Resources FY2025 – Share Buybacks & A Massive New Dividend Payout

4 Surprising Takeaways from TSH Resources’ 2025 Performance How does a massive plantation group build...
Load more

Latest articles

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...